NK cell-based cancer immunotherapy

Drug News and Perspectives

Volumn 20, Issue 3, 2007, Pages 155-163

  Stagg, John ^a   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BORTEZOMIB; CPG OLIGODEOXYNUCLEOTIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 2; IRINOTECAN; PACLITAXEL; PROTEASOME INHIBITOR; RECOMBINANT INTERLEUKIN 15; RITUXIMAB; TRASTUZUMAB;

ADAPTIVE IMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CPG ISLANDS; CYTOKINES; DEFENSINS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MYCOBACTERIUM BOVIS; NEOPLASMS; OLIGONUCLEOTIDES; RECEPTORS, IMMUNOLOGIC;

EID: 34250338884     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.3.1092096     Document Type: Review

References (86)

1. Gattinoni, L., Powell, D.J. Jr., Rosenberg, S.A. and Restifo, N.P. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006, 6: 383-93.
2. zum Buschenfelde, C.M., Hermann, C., Schmidt, B. et al. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002, 62: 2244-7.
3. Smyth, M.J., Hayakawa, Y., Takeda, K. and Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002, 2: 850-61.
4. Degli-Esposti, M.A. and Smyth, M.J. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5: 112-24.
5. Pulendran, B. and Ahmed, R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006, 124: 849-63.
6. Munz, C., Steinman, R.M. and Fujii, S. Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity. J Exp Med 2005, 202: 203-7.
7. Andrews, D.M., Andoniou, C.E., Scalzo, A.A. et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 2005, 42: 547-55.
8. Moretta, A. Natural killer cells and dendritic cells: Rendezvous in abused tissues. Nat Rev Immunol 2002, 2: 957-64.
9. Gasser, S. and Raulet, D.H. The DNA damage response arouses the immune system. Cancer Res 2006, 66: 3959-62.
10. Dunn, G.P., Old, L.J. and Schreiber, R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22: 329-60.
11. Smyth, M.J. and Trapani, J.A. Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol 2001, 22: 409-11.
12. Cui, Z., Willingham, M.C. and Hicks, A.M. Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A 2003, 100: 6682-7.
13. Hicks, A.M., Riedlinger, G., Willingham, M.C. et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A 2006, 103: 7753-8.
14. Smyth, M.J., Crowe, N.Y. and Godfrey, D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001, 13: 459-63.
15. Street, S.E., Hayakawa, Y., Zhan, Y. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004, 199: 879-84.
16. Smyth, M.J., Thia, K.Y., Cretney, E. et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999, 162: 6658-62.
17. Takeda, K., Hayakawa, Y., Smyth, M.J. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001, 7: 94-100.
18. Smyth, M.J., Cretney, E., Takeda, K. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon-gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001, 193: 661-70.
19. Smyth, M.J., Cretney, E., Kelly, J.M. et al. Activation of NK cell cytotoxicity. Mol Immunol 2005, 42: 501-10.
20. Peritt, D., Robertson, S., Gri, G. et al. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998, 161: 5821-4.
21. Robertson, M.J. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002, 71: 173-83.
22. Roda, J.M., Parihar, R., Magro, C. et al. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006, 66: 517-26.
23. Meylan, E., Tschopp, J. and Karin, M. Intracellular pattern recognition receptors in the host response. Nature 2006, 442: 39-44.
24. Shi, Y., Evans, J.E. and Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425: 516-21.
25. Hayakawa, Y. and Smyth, M.J. Related NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 2006, 18: 176-85.
26. Moretta, A., Bottino, C., Vitale, M. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19: 197-223.
27. Bauer, S., Groh, V., Wu, J. et al. Activation ofNK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285: 727-9.
28. Cosman, D., Mullberg, J., Sutherland, C.L. et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14: 123-33.
29. Cerwenka, A., Bakker, A.B., McClanahan, T. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000, 12:721-7.
30. Carayannopoulos, L.N., Naidenko, O.V., Fremont, D.H. et al. Cutting edge: Murine UL16-binding protein-like transcript 1: A newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002, 169: 4079-83.
31. Diefenbach, A., Jensen, E.R., Jamieson, A.M. and Raulet, D.H. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413: 165-71.
32. Gasser, S., Orsulic, S., Brown, E.J. and Raulet, D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436: 1186-90.
33. Smyth, M.J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W.M. and Hayakawa, Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005, 202: 583-8.
34. Groh, V., Wu, J., Yee, C. and Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419: 734-8.
35. Coudert, J.D., Zimmer, J., Tomasello, E. et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005, 106: 1711-7.
36. Li, M.O., Wan, Y.Y., Sanjabi, S. et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24: 99-146.
37. Ito, M., Maruyama, T., Saito, N. et al. Killer cell lectin-like receptor Gl binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006, 203: 289-95.
38. Carlyle, J.R., Jamieson, A.M., Gasser, S. et al. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci U S A 2004, 101: 3527-32.
39. Trinchieri, G. and Valiante, N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993, 12: 218-34.
40. Assarsson, E., Kambayashi, T., Persson, CM. et al. 2B4/CD48-mediated regulation of lymphocyte activation and function. J Immunol 2005, 175: 2045-9.
41. Schatzle, J.D., Sheu, S., Stepp, S.E. et al. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci USA 1999, 96: 3870-5.
42. Tahara-Hanaoka, S., Shibuya, K., Kai, H. et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006, 107: 1491-6.
43. Fan, Z., Yu, P., Wang, Y. et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 107: 1342-51.
44. Ma, A., Koka, R. and Burkett, P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24: 657-79.
45. Gresser, I. and Belardelli, F. Endogenous Type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002, 13: 111-8.
46. Smyth, M.J., Cretney, E., Kershaw, M.H. et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 202: 275-93.
47. Oniki, S., Nagai, H., Horikawa, T., Furukawa, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66: 6395-404.
48. Atkins, M.B., Lotze, M.T., Dutcher, J.P. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17: 2105-16.
49. Leonard, W.J. and Spolski, R. Interleukin-21: A modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5: 688-98.
50. Smyth, M.J., Swann, J., Kelly, J.M. et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 200: 1325-35.
51. Takaki, R., Hayakawa, Y., Nelson, A. et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175: 2167-73.
52. Yamaguchi, T. and Sakaguchi, S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006, 16: 115-23.
53. Curiel, T.J., Coukos, G., Zou, L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10: 942-9.
54. Smyth, M.J., Teng, M.W., Swann, J. et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176: 1582-7.
55. Ghiringhelli, F., Menard, C., Terme, M. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005, 202: 1075-85.
56. Burns, L.J., Weisdorf, D.J., DeFor, T.E. et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplant 2003, 32: 177-86.
57. Goldfarb, R.H., Ohashi, M., Branson, K.W et al. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Res 1998, 18(3A): 1441-6.
58. Ruggeri, L., Capanni, M., Urbani, E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295: 2097-100.
59. Miller, J.S., Soignier, Y. Panoskaltsis-Mortari, A. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells inpatients with cancer. Blood 2005, 105: 3051-7.
60. Igarashi, T., Wynberg, J., Srinivasan, R. et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004, 104: 170-7.
61. Lamb, L.S. Jr., Gee, A.P., Henslee-Downey, P.J. et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998, 21: 461-71.
62. Nguyen, S., Dhedin, N., Vernant, J.P. et al. NK-cell reconstituiion after haploidentical hematopoietic stem-cell transplantations: Immaturity ofNK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005, 105: 4135-42.
63. Adams, G.P. and Weiner, L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23: 1147-57.
64. Clynes, R.A., Towers, T.L., Presta, L.G. and Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6: 443-6.
65. Sampson, J.H. et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000, 97: 7503-8.
66. Cooley, S., Burns, L.J., Repka, T. and Miller, J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999, 27: 1533-41.
67. Carson, W.E., Parihar, R., Lindemann, M.J. et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001, 31: 3016-25.
68. Parihar, R., Dierksheide, J., Hu, Y. and Carson, W.E. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002, 110: 983-92.
69. Parihar, R., Nadella, P., Lewis, A. et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 2004, 10: 5027-37.
70. Gluck, W.L., Hurst, D., Yuen, A. et al. Phase I studies of interleukin (lL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10: 2253-64.
71. Ansell, S.M., Witzig, T.E., Kurtin, P.J. et al. Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002 Jan 1, 99: 67-74.
72. Roda, J.M., Parihar, R., Lehman, A. et al. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 177: 120-9.
73. Roda, J.M., Parihar, R. and Carson, W.E. 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 2005, 175: 1619-27.
74. Brandau, S., Riemensberger, J., Jacobsen, M. et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001, 92: 697-702.
75. Suttmann, H., Riemensberger, J., Bentien, G. et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006, 66: 8250-7.
76. Raj, P.A. and Dentino, A.R. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002, 206: 9-18.
77. Ma, X.T., Xu, B., An, L.L. et al. Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Cancer Res 2006, 66: 1169-76.
78. Ravi, R., Jain, A.J., Schulick, R.D. et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004, 64: 9105-14.
79. Voelkel-Johnson, C., Hannun, Y.A. and El-Zawahry, A. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Mol Cancer Ther 2005, 4: 1320-7.
80. Lundqvist, A., Abrams, S.I., Schrump, D.S. et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006 Jul 15, 66: 7317-25.
81. Armeanu, S., Bitzer, M., Lauer, U.M. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65: 6321-9.
82. Taieb, J., Chaput, N., Menard, C. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006, 12: 214-9.
83. Chan, C.W., Crafton, E., Fan, H.N. et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006, 12: 207-13.
84. Cebo, C., Da Rocha, S., Wittnebel, S. et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GMI expression, and synapse formation. J Immunol 2006, 176: 864-72.
85. Baron, F., Turhan, A.G., Giron-Michel, J. et al. Leukemic target susceptibility to natural killer cytotoxicity: Relationship with BCR-ABL expression. Blood 2002, 99: 2107-13.
86. Lee, C.F., Chang, S.Y., Hsieh, D.S. and Yu, D.S. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Cancer Gene Ther 2004, 11: 194-207.